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What’s new? 
• Hypoglycaemia is associated with worse outcomes in inpatients with diabetes. At 
present there is no targeted and validated prediction model for identifying patients 
with an increased risk of hypoglycaemia. 
• We performed a retrospective analysis of inpatient admissions with diabetes to 
develop a prediction model for hypoglycaemia incorporating routinely collected 
biochemical data.  
• We found that the occurrence of hypoglycaemia could be predicted by a model 
incorporating background medication, ethnicity, age, admission type and 
laboratory measurements. 
• Model performance indicates potential clinical utility to identify patients at risk of 
hypoglycaemia during their inpatient stay, which could lead to improved patient 
management and outcomes.  
Abstract 
Aims 
Inpatient hypoglycaemia in patients with diabetes mellitus is associated with excess 
mortality, increased length of stay and increased complication rate. The objective of 
this study was to explore whether a quantitative approach to identify hospitalized 
patients with diabetes at risk of hypoglycaemia could be feasible by incorporating 
routine biochemical, haematological and prescription data. 
Methods 
A retrospective cross-sectional analysis of all diabetic admissions (n=9,584) from 1st 
January 2014 to 31st December 2014 was performed. Hypoglycaemia was defined as 
a blood glucose level of < 4 mmol/L.  The prediction model was constructed using 
multivariable logistic regression, populated by clinically important variables and 
routine laboratory data. 
Results 
Using a pre-specified variable selection strategy, it was shown that the occurrence of 
inpatient hypoglycaemia could be predicted by a combined model taking into account 
background medication (type of insulin, use of sulphonylurea), ethnicity (Black and 
Asian), age (75+ years old), type of admission (emergency) and laboratory 
measurements (eGFR, CRP, sodium and albumin). ROC curve analysis revealed that 
the Area Under the Curve (AUC) was 0.733 (95% CI 0.719 to 0.747). The cut-off 
point chosen to maximize both sensitivity and specificity was 0.15. AUC obtained 
from internal validation did not differ from the primary model (0.731 (95% CI 0.717 
to 0.746)).  
  
Conclusions 
The inclusion of routine biochemical data, available at the time of admission, can add 
prognostic value to demographic and medication history. The predictive performance 
of the constructed model indicates potential clinical utility to identify patients at risk 
of hypoglycaemia during their inpatient stay. 
 
Introduction  
Hospitalised patients with diabetes have high infection rates [1-4], longer length of 
stay [5-7] and increased mortality (10% higher) [8]. Hypoglycaemia is one of the 
important determining events for this worse prognosis, which can be reflected in 
excess mortality, increased length of stay and increased complications amongst 
patients with diabetes [9-11]. Hence, predicting the risk of hypoglycaemia in 
hospitalized patients with diabetes mellitus and preventing its occurrence in a 
selected, high-risk subset of them through active monitoring or therapeutic 
modifications may be an efficient way to improve outcomes. 
However, a targeted and validated prediction model for identifying inpatients 
with diabetes at an increased risk of hypoglycaemia is still missing. The main reason 
is the heterogeneity in populations, thresholds for hypoglycaemia, underlying diseases 
and co-morbidities across relevant studies [11-19]. This is why the Joint British 
Diabetes Societies’ (JBDS) position currently advocates a non-quantitative approach 
with regard to risk of inpatient hypoglycaemia in patients with diabetes [20]. 
Specifically, the recommended approach would be to consider medical or lifestyle 
risk factors, such as strict glucose management, history of severe hypoglycemic 
events, duration of insulin use, severe liver failure, renal failure, terminal illness or 
increasing age and alcohol use respectively. 
To explore whether a quantitative approach to identify hospitalized patients 
with diabetes at risk of hypoglycaemia could be feasible and construct a relevant 
prediction model incorporating routine biochemical data collected at admission, we 
performed a retrospective analysis of admissions with diabetes.  
 
Methods 
All hospitalized adult (>16 years old) patients with diabetes mellitus in the general 
ward of our Institution were considered as potentially eligible, irrespective of the 
primary diagnosis. The observation period was from 1st January 2014 to 31st 
December 2014. The diagnosis of diabetes mellitus was consolidated by the presence 
of relevant Patient Administration System (PAS) discharge codes for diabetes or the 
presence of a continuous anti-hyperglycemic medication in the electronic medical 
record system (Patient Information and Communication System (PICS)). The 
diagnosis of diabetes was also ensured by cross-checking the PAS database for the 
International Classification of Diseases version 10 (ICD-10) diabetes codes (E10 – 
E14) retrospectively for the previous 10 years, up to 2004. Prescription of metformin 
or short acting insulin in the absence of a diabetes code was considered an exclusion 
criterion to ensure case (diabetes mellitus) definition. Patients admitted to ITU were 
excluded from the analysis.  
The outcome of interest was the occurrence of hypoglycaemia, which was defined as 
a blood glucose level of < 4 mmol/L (point of care or laboratory blood glucose 
measurement).   
 
  
Statistical Analysis 
Baseline differences in continuous data between hypoglycaemic and non 
hypoglycaemic groups were explored using the Student’s T-test or Mann-Whitney U 
test according to distribution.  Differences in dichotomous data were explored using a 
Chi-squared test.  
The prediction model was constructed on the basis of a multivariable logistic 
regression model with hypoglycaemia as the dependent outcome.  This model was 
populated by clinically important variables, as identified by previous literature, 
including laboratory results as recorded in PICS. All variables with a p-value at 
significance level of 20% (p = 0.20) in the univariate analysis were included in the 
multivariable logistic regression model (Supplementary Table 1). In cases where two 
variables were statistically significant but highly correlated, one was chosen based on 
clinical familiarity. Continuous data (for example age) were also analyzed as 
categories to inspect potential non-linear effects. Area Under the Curve analysis was 
performed to assess the predictive performance of the final model. A decision 
threshold was selected with the intent of maximizing both sensitivity and specificity. 
Positive and negative predictive values were calculated using the prevalence of 
hypoglycaemia in this dataset. 
Internal validation was assessed using bootstrapping, in which sample datasets 
the same size as the original dataset are repeatedly resampled, with replacement, and 
model parameters are re-estimated and averaged over the samples [21]; this identifies 
any shrinkage necessary to reduce model over-optimism due to over-fitting. Missing 
data were handled by a chained multiple imputation technique with predictive mean 
matching. Bootstrapped results from each of the imputed datasets were combined 
using Rubin’s rule. In sensitivity analysis, missing values were replaced by values in 
the normal range for the given clinical pathology test. Model calibration was assessed 
by plotting predicted probability of hypoglycaemia against observed probability. 
Significance level was set at 5% and all analyses were implemented in Stata 13.0. 
 
Results 
Flow chart  
From a total of 106,580 patients admitted to our Institution during 2014, 57,922 
admissions were eligible (emergency or elective admissions) and of those, 9,584 
admissions were in patients with diabetes. Hypoglycaemia occurred in 1,327 (13.8%) 
admissions with diabetes while the remaining 8,257 (86.2%) did not have a 
hypoglycaemic event.  A flow chart summarizing the selection process along with 
reasons for exclusion is presented in Figure 1. 
6,187 unique patients made up the 9,584 admissions included in the analysis. 
Of the 1,792 patients who contributed two or more admissions, 664 experienced a 
hypoglycaemic episode; none of these 664 patients had a hypoglycaemic episode in 
more than one admission. 
Baseline characteristics 
A table summarizing differences in the baseline demographics and medication history 
is presented in Table 1 and 2. Patients in the hypoglycaemia group were older, more 
deprived, with higher comorbidities and more likely to belong to an ethnic minority 
group compared to the group without hypoglycaemia. Insulin use and sulphonylureas 
were also proportionally more common in the hypoglycaemia group (Table 2). A 
table summarizing differences in the baseline laboratory measurements is presented in 
Table 3. Patients in the hypoglycaemia group were more likely to have elevated 
inflammation markers (C-reactive protein, CRP levels), electrolyte disturbances or 
have anaemia. 
Final model 
Using a pre-specified variable selection strategy, younger age categories, female 
gender, hyperkalaemia, an elevated neutrophil count and anaemia were not found to 
be significant predictors of hypoglycaemia in the multivariable logistic regression. 
Elderly greater than 75 years, Insulin and  sulphonylureas therapy, Black and Asian 
ethnicity, emergency admissions, lower eGFR, higher CRP, hyponatraemia 
(<125mmol/L) and hypo-albuminaemia were the strongest predictors of 
hypoglycaemia in patients with diabetes mellitus admitted in the general ward. The 
final model (prior to bootstrapping) is presented in the Table 4. 
In sensitivity analysis, we used multilevel modelling (xtlogit) to allow for any 
possible correlation between multiple admissions for an individual patient; this made 
very little difference to the model parameters. 
Model performance and internal validity  
ROC curve analysis revealed that the Area Under the Curve (AUC) was 0.733 (95% 
CI 0.719 to 0.747) (Figure 2). The cut-off point chosen to maximize both sensitivity 
and specificity was 0.15 predicted probability of hypoglycaemia, with these 
corresponding values being 59.3% and 73.7% respectively. At this cut-off the positive 
predictive value was 26.6% and the negative predictive value was 91.8%. A confusion 
matrix describing model performance is shown in Figure 3. The model was internally 
validated by bootstrapping; model coefficients were unchanged and test statistics 
were similar to the primary model, indicating no evidence of over-fitting: AUC 0.731 
(95% CI 0.717 to 0.746), sensitivity 59.3%, specificity 73.4%, positive predictive 
value 26.4%, and negative predictive value 91.8%. Visual assessment of the 
calibration plot (Figure 4) suggests that model calibration is good (i.e. predicted 
probabilities of hypoglycaemia are similar to observed probabilities). 
In sensitivity analysis, missing clinical pathology test results were replaced 
with values in the normal range (Supplementary Table 2). This had little effect on the 
model performance: AUC 0.735 (95% CI 0.721 to 0.749), sensitivity 60.4%, 
specificity 73.4%, positive predictive value 26.8%, and negative predictive value 
92.0%. 
 
Discussion 
In this retrospective analysis of all diabetic admissions, we found that the occurrence 
of inpatient hypoglycaemia could be predicted by a combined model taking into 
account background medication (type of insulin, use of sulphonylurea use), ethnicity 
(Black and Asian), age (75+ years old), type of admissions (emergency) and 
laboratory measurements (eGFR, CRP, sodium and albumin).  
Considering that inpatient hypoglycaemia is significantly associated with 
inpatient mortality and increased length of hospital stay [10, 11] and that real-time 
generated alerts using a validated computerized predictive algorithm may 
significantly reduce its occurrence [16], the findings of the present study could 
provide a robustly validated basis to improve inpatient safety and outcomes. 
Importantly, this study also showed that the inclusion of routine biochemical data 
(such as CRP, albumin, eGFR and sodium), available at the time of admission, could 
add prognostic value to demographic and medication history, thus providing a more 
holistic and optimized approach in the prediction of hypoglycemic events.  
On the other hand, the findings of the present study should be interpreted in 
the context of its limitations. First external validity, that is assessing the model in a 
different environment on a different population, would be a prerequisite before 
recommending its adoption in clinical practice. Moreover, the extent of missing data 
with regard to glycated hemoglobin (HbA1c) prevented the plausible exploration of 
tight versus poor glycemic control as a predictor of hypoglycaemia. The study used 
routinely collected observational data, and therefore there may be unobserved 
confounding for which it was not possible make adjustments in the analysis. 
However, this does not vitiate the utility of the model or the observed association 
between the predictor variables and the outcome. 
Taking the above into consideration and using the largest dataset of diabetic 
admissions to date, we suggest that the occurrence of inpatient hypoglycaemia may be 
predicted by a combined model using background medication ethnicity, age, type of 
admission and routine laboratory measurements as independent predictors. The 
predictive performance of the constructed model indicates potential clinical utility in 
identifying patients at high risk of inpatient hypoglycaemia. 
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Table 1.  Baseline demographics  
Patient Demographics Normoglycaemia 
(>3.9 mmol/L;  
N= 8,257) 
Hypoglycaemia 
(≤3.9 mmol/L;  
N= 1,327) 
P-value 
Age median (IQR) 68 (56-78) 70 (57-80) 0.032 
Age categories N (%)   < 0.001 
16-44 723 (8.8) 128 (9.7)  
45-54 1,118 (13.5) 154 (11.6)  
55-64 1,574 (19.1) 218 (16.4)  
65-74 2,095 (25.4) 294 (22.2)  
75-84 1,858 (22.5) 361 (27.2)  
≥ 85 889 (10.8) 172 (13.0)  
Sex N (%)0   0.026 
Male 4,566 (55.4) 691 (52.1)  
Female 3,682 (44.6) 636 (47.9)  
Ethnicity N (%)0   < 0.001 
Caucasian 5,657 (68.5) 855 (64.4)  
Black 455 (5.5) 117 (8.8)  
Asian 1,765 (21.4) 298 (22.5)  
Other 380 (4.6) 57 (4.3)  
IMD deprivation quintile N 
(%)0 
  0.025 
Least deprived 1 366 (4.5) 47 (3.6)  
2                  531(6.5) 85 (6.5)  
3 1,657 (20.4) 239 (18.3)  
4 1,675 (20.6) 246 (18.8)  
Most deprived 5 3,915 (48.1) 689 (52.8)  
Type of Admission N (%)   < 0.001 
Elective 1,882 (22.8) 144 (10.9)  
Emergency 6,375 (77.2) 1,183 (89.2)  
Modified† Charlson 
Comorbidity score N (%) 
  < 0.001 
0 3,807 (46.1) 429 (32.3)  
1 1,524 (18.5) 214 (16.1)  
2 or more 2,926 (35.4) 684 (51.5)  
IMD: Index of Multiple Deprivation. Missing Data: 0 <1.5%, otherwise nil. 
†Charlson score with diabetes scores removed. 
  
 Table 2: Medication history 
 
Patient  
Medications 
Normoglycaemia 
(>3.9 mmol/L; 
N= 8,257) 
Hypoglycaemia 
(<3.9 mmol/L; 
N= 1,327) 
P-value 
 
Insulin N (%)    
Short Acting 887 (10.7) 373 (28.1) < 0.001 
Intermediate Acting 184 (2.2) 88 (6.6) < 0.001 
Long Acting 1,085 (13.1) 381 (28.7) < 0.001 
Sulphonylureas N (%) 1,370 (16.6) 334 (25.2) < 0.001 
Metformin N (%) 3,145 (38.1) 501 (37.8) 0.816 
Thiazolidinediones N (%) 139 (1.7) 29 (2.2) 0.196 
Incretin mimetics N (%) 107 (1.3) 13 (1.0) 0.336 
DPP-4 inhibitors N (%) 691 (8.4) 124 (9.3) 0.237 
Other antidiabetic 
medications† N (%) 
36 (0.4) 14 (1.1) 0.004 
Reg.: Regulator. † Alpha-glucosidase, prandial glucose regulator, SGLT2 
inhibitors. Common combinations of medications are shown in Supplementary 
Table 3. 
 
  
Table 3. Baseline laboratory characteristics considered for the prediction model 
Patient  
Laboratory Results 
Normoglycaemia 
(>3.9 mmol/L; 
N= 8,257) 
Hypoglycaemia 
(≤3.9 mmol/L; 
N= 1,327) 
P-value 
 
Electrolytes and renal function    
Sodium mean (SD)◊ 137.0 (4.8) 136.3 (5.7) < 0.001 
Sodium N (%)◊   < 0.001 
< 125 mmol/L 110 (1.6) 43 (3.4)  
125-134 mmol/L 1,611 (23.1) 377 (29.9)  
135-144 mmol/L 5,076 (72.9) 796 (63.2)  
145-154 mmol/L 160 (2.3) 37 (2.9)  
≥ 155 mmol/L 8 (0.1) 7 (0.6)  
Potassium mean (SD) ◊ 4.5 (0.6) 4.6 (0.8) < 0.001 
Potassium N (%)◊   < 0.001 
< 3 mmol/L 28 (0.4) 9 (0.8)  
3-6 mmol/L 6,139 (97.2) 1,046 (94.2)  
≥ 6 mmol/L 150 (2.4) 56 (5.0)  
Creatinine median (IQR) ◊ 88 (68, 127) 105 (75, 173) < 0.001 
eGFR median (IQR)◊ 66 (43, 88) 51.5 (30, 78) < 0.001 
eGFR N (%)◊   < 0.001 
≥ 90 1,686 (24.2) 230 (18.3)  
60-89 2,352 (33.8) 303 (24.1)  
30-59 1,860 (26.7) 411 (32.7)  
15-29 533 (7.7) 168 (13.4)  
< 15 524 (7.5) 146 (11.6)  
Infection / Inflammation marker    
CRP  median (IQR)* 13 (4, 47) 24 (6, 77) < 0.001 
CRP N (%)*   < 0.001 
< 10 mg/L 2,622 (44.1) 413 (34.3)  
10-49 mg/L 1,902 (32.0) 377 (31.3)  
50-99 mg/L 689 (11.6) 175 (14.5)  
≥ 100 mg/L 728 (12.3) 240 (19.9)  
Haematology Tests    
Haemoglobin mean (SD)◊ 120.8 (21.4) 115.5 (21.4) < 0.001 
Haemoglobin ◊    < 0.001 
< 80 g/L 220 (3.2) 60 (4.8)  
80-109 g/L 1,732 (25.2) 413 (33.0)  
≥ 110 g/L 4,911 (71.6) 780 (62.3)  
Neutrophil median (IQR)◊ 6.3 (4.5, 8.9) 7.0 (4.8, 10.3) < 0.001 
Neutrophil N (%)◊   < 0.001 
< 2 157 (2.3) 32 (2.5)  
2-7.9 4,476 (65.0) 718 (57.1)  
≥ 8 2,261 (32.8) 508 (40.3)  
Liver function test    
Albumin mean (SD)◊ 40.1 (5.4) 37.9 (6.3) < 0.001 
Albumin N (%)◊   < 0.001 
< 25 77 (1.8) 34 (2.8)  
25-35 862 (13.1) 305 (24.7)  
≥ 35 5,654 (85.8) 898 (72.6)  
Bilirubin median (IQR)◊ 7 (5, 11) 7 (5, 12) 0.742 
Missing Data: ◊ 5-20%, * 21-30% 
 
Table 4. Results of the multivariable logistic regression analysis 
Variables (n, % observations 
with imputed data) 
Regression Coefficient (95% CI) OR (95% CI) P-value 
Age categories                   
16-44 0.19 (-0.08 to 0.45) 1.20 (0.92 to 1.58) 0.177 
*45-54 - 1 - 
55-64 0.03 (-0.20 to 0.26) 1.03 (0.82 to 1.30) 0.786 
65-74 0.03 (-0.20 to 0.25) 1.03 (0.82 to 1.28) 0.823 
≥ 75 0.25 (0.04 to 0.46) 1.28 (1.04 to 1.59) 0.022 
Sex    
                         *Male - 1 - 
Female 0.06 (-0.07 to 0.18) 1.06 (0.94 to 1.20) 0.362 
Ethnicity     
*Caucasian - 1 - 
Black 0.53 (0.30 to 0.77) 1.71 (1.35 to 2.16) < 0.001 
Asian 0.17 (0.02 to 0.33) 1.19 (1.02 to 1.39) 0.027 
Other 0.20 (-0.10 to 0.50) 1.22 (0.90 to 1.66) 0.198 
Admission Type    
*Elective - 1 - 
Emergency 0.70 (0.51 to 0.89) 2.01 (1.66 to 2.43) < 0.001 
Insulin    
Short Acting 0.86 (0.71 to 1.02) 2.37 (2.03 to 2.78) < 0.001 
Intermediate Acting 0.71 (0.42 to 0.99) 2.03 (1.53 to 2.69) < 0.001 
Long Acting 0.70 (0.55 to 0.85) 2.02 (1.73 to 2.35) < 0.001 
Sulphonylureas  0.57 (0.42 to 0.72) 1.77 (1.53 to 2.05) < 0.001 
Sodium (1,350, 14.1%)    
<125 mmol/L 0.55 (0.16 to 0.93) 1.73 (1.17 to 2.54) 0.006 
125-134 mmol/L 0.08 (-0.07 to 0.23) 1.08 (0.93 to 1.25) 0.291 
*135-144 mmol/L - 1 - 
145-154 mmol/L 0.09 (-0.30 to 0.48) 1.09 (0.74 to 1.61) 0.668 
≥ 155 mmol/L 1.09 (-0.01 to 2.19) 2.97 (0.99 to 8.91) 0.052 
Potassium (2,147, 22.4%)     
< 3 mmol/L 0.34 (-0.47 to 1.14) 1.40 (0.63 to 3.13) 0.413 
*3 – 6 mmol/L - 1 - 
≥ 6 mmol/L 0.08 (-0.28 to 0.43) 1.08 (0.76 to 1.54) 0.672 
eGFR (1,362, 14.2%)    
*≥ 90 - 1 - 
60-89 -0.02 (-0.22 to 0.17) 0.98 (0.80 to 1.19) 0.815 
30-59 0.34 (0.14 to 0.54) 1.40 (1.15 to 1.71) 0.001 
15-29 0.54 (0.28 to 0.79) 1.71 (1.32 to 2.20) < 0.001 
< 15 0.41 (0.14 to 0.67) 1.50 (1.16 to 1.95) 0.002 
CRP (2,429, 25.3%)    
*0 - 10 - 1 - 
10 - 49 0.10 (-0.06 to 0.26) 1.10 (0.94 to 1.30) 0.230 
50 - 99 0.27 (0.05 to 0.49) 1.31 (1.06 to 1.63) 0.014 
≥ 100 0.37 (0.15 to 0.58) 1.44 (1.16 to 1.78) 0.001 
Albumin (1,745, 18.2%)    
< 25 0.61 (0.17 to 1.06) 1.85 (1.19 to 2.88) 0.007 
25-35 0.49 (0.31 to 0.66) 1.63 (1.37 to 1.94) < 0.001 
*≥ 35 - 1 - 
Neutrophil count (1,423, 14.8%)    
<2  0.11 (-0.29 to 0.52) 1.12 (0.75 to 1.66) 0.584 
*2-8 - 1 - 
≥ 8 0.06 (-0.08 to 0.20) 1.06 (0.92 to 1.23) 0.405 
Haemoglobin (1,459, 15.2%)    
< 80 -0.03 (-0.35 to 0.30) 0.98 (0.70 to 1.35) 0.880 
80-110 0.02 (-0.12 to 0.17) 1.02 (0.88 to 1.19) 0.742 
*≥ 110 - 1 - 
Constant -3.57 (-3.86 to -3.27)  < 0.001 
Figure 1. Flow diagram of included patients with diabetes 
 
 
 
Figure 2. ROC curve for fitted model 
 
 
Figure 3. Confusion matrix showing actual and predicted numbers of 
hypoglycaemic outcomes 
Predicted 
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Figure 4. Calibration plot showing predicted and observed probabilities of 
hypoglycaemia 
 
  
Supplementary Table 1.  Findings of the univariate analyses. 
Variables Odds Ratio 95% CI P-value 
Age categories    
16-44 1.29 1.00 to 1.65 0.051 
  *45-54 1 - - 
55-64 1.01 0.81 to 1.25 0.961 
65-74 1.02 0.83 to 1.25 0.861 
≥ 75 1.41 1.16 to 1.71 < 0.001 
Gender     
*Male 1 - - 
Female 1.14 1.02 to 1.28 0.026 
Ethnicity     
*Caucasian 1 - - 
Black 1.70 1.37 to 2.11 < 0.001 
Asian 1.12 0.97 to 1.29 0.127 
Other 0.99 0.74 to 1.32 0.959 
IMD deprivation quintile   
*Least deprived 1 1 - - 
2 1.25 0.85 to 1.82 0.256 
3 1.12 0.81 to 1.57 0.494 
4 1.14 0.82 to 1.59 0.428 
Most deprived 5 1.37 1.00 to 1.88 0.049 
Type of Admission     
*Elective    
Emergency 2.43 2.02 to 2.90 <0.001 
Modified† Charlson    
*0 1 - - 
1 1.25 1.05 to 1.48 0.013 
≥ 2 2.07 1.82 to 2.36 < 0.001 
IMD: Index of Multiple Deprivation. †Modified Charlson: Charlson score minus 
Diabetes. 
 
 
Variables Odds Ratio 95% CI P-value 
Insulin    
Short Acting 3.25 2.83 to 3.73 < 0.001 
Intermediate Acting 3.12 2.40 to 4.05 < 0.001 
Long Acting 2.66 2.33 to 3.05 < 0.001 
Any  3.36 2.98 to 3.79 < 0.001 
Sulphonylureas  1.69 1.47 to 1.94 < 0.001 
Metformin  0.99 0.87 to 1.11 0.816 
Thiazolidinediones 1.30 0.87 to 1.96 0.197 
Incretin mimetics 0.75 0.42 to 1.34 0.338 
DPP-4 inhibitors 1.13 0.92 to 1.38 0.237 
 
  
 Variables Odds Ratio 95% CI P-value 
Sodium     
<125 mmol/L 2.49 1.73 to 3.58 < 0.001 
125-134 mmol/L 1.53 1.34 to 1.75 < 0.001 
*135-144 mmol/L 1 - - 
145-154 mmol/L 1.46 1.01 to 2.11 0.044 
≥155 mmol/L 5.78 2.06 to 16.24 0.001 
Potassium      
<3 mmol/L 1.78 0.85 to 3.75 0.129 
*3-6 mmol/L 1 - - 
≥6 mmol/L 2.26 1.66 to 3.06 < 0.001 
eGFR       
*≥ 90 1 - - 
60-89 0.93 0.77 to 1.12 0.424 
30-59 1.62 1.35 to 1.93 < 0.001 
15-29 2.34 1.86 to 2.94 < 0.001 
< 15 2.12 1.69 to 2.67 < 0.001 
CRP      
          *0-10 1   
10-49 1.32 1.13 to 1.53 < 0.001 
50-99 1.74 1.43 to 2.11 < 0.001 
≥ 100 2.28 1.91 to 2.72 < 0.001 
Albumin    
< 25 2.79 1.84 to 4.23 < 0.001 
25-35 2.25 1.93 to 2.61 <0.001 
*≥ 35 1 - - 
Neutrophil count    
< 2 1.21 0.83 to 1.77 0.330 
*2-8 1 - - 
≥ 8 1.44 1.27 to 1.63 < 0.001 
Haemoglobin    
< 80 1.76 1.31 to 2.37 < 0.001 
80-109 1.49 1.31 to 1.70 < 0.001 
*≥ 110 1 -  
*Comparator. 
 
  
Supplementary Table 2. Results of analysis replacing missing clinical pathology test 
results with values in the normal range. 
 
Variables 
Regression 
Coefficient (95% CI) 
P-value 
Boostrapped Regression 
Coefficient (95% CI) 
P-value 
Age categories                    
16-44 0.20 (-0.07 to 0.47) 0.139 0.20 (-0.07 to 0.48) 0.144 
*45-54 - - - - 
55-64 0.02 (-0.21 to 0.26) 0.836 0.02 (-0.21 to 0.26) 0.836 
65-74 0.01 (-0.21 to 0.23) 0.934 0.01 (-0.22 to 0.23) 0.935 
≥ 75 0.24 (0.02 to 0.45) 0.029 0.24 (0.02 to 0.45) 0.033 
Sex     
                         *Male - - - - 
Female 0.05 (-0.07 to 0.18) 0.395 0.05 (-0.07 to 0.18) 0.399 
Ethnicity     
* Caucasian - - - - 
Black 0.56 (0.33 to 0.80) < 0.001 0.56 (0.32 to 0.80) < 0.001 
Asian 0.18 (0.02 to 0.33) 0.025 0.18 (0.02 to 0.34) 0.029 
Other 0.23 (-0.07 to 0.54) 0.131 0.23 (-0.07 to 0.54) 0.132 
Admission Type     
*Elective - - - - 
Emergency 0.50 (0.30 to 0.70) < 0.001 0.50 (0.30 to 0.70) < 0.001 
Insulin     
Short Acting 0.82 (0.66 to 0.98) < 0.001 0.82 (0.65 to 0.99) < 0.001 
Intermediate Acting 0.68 (0.40 to 0.97) < 0.001 0.68 (0.38 to 0.98) < 0.001 
Long Acting 0.69 (0.54 to 0.84) < 0.001 0.69 (0.53 to 0.85) < 0.001 
Sulphonylureas  0.54 (0.40 to 0.69) < 0.001 0.54 (0.39 to 0.70) < 0.001 
Sodium      
<125 mmol/L 0.57 (0.18 to 0.96) 0.004 0.57 (0.17 to 0.97) 0.005 
125-134 mmol/L 0.06 (-0.08 to 0.21) 0.413 0.06 (-0.09 to 0.22) 0.440 
*135-144 mmol/L - - - - 
145-154 mmol/L 0.08 (-0.31 to 0.48) 0.672 0.08 (-0.35 to 0.51) 0.700 
≥ 155 mmol/L 1.05 (-0.05 to 2.14) 0.061 1.05 (-0.21 to 2.30) 0.102 
Potassium       
< 3 mmol/L 0.42 (-0.39 to 1.23) 0.311 0.42 (-0.37 to 1.22) 0.300 
*3 – 6 mmol/L - - - - 
≥ 6 mmol/L 0.02 (-0.33 to 0.36) 0.931 0.02 (-0.35 to 0.38) 0.934 
eGFR        
*≥ 90 - - - - 
60-89 0.03 (-0.15 to 0.21) 0.727 0.03 (-0.15 to 0.21) 0.729 
30-59 0.39 (0.21 to 0.57) < 0.001 0.39 (0.20 to 0.57) < 0.001 
15-29 0.57 (0.33 to 0.81) < 0.001 0.57 (0.33 to 0.81) < 0.001 
< 15 0.40 (0.15 to 0.65) 0.002 0.40 (0.14 to 0.66) 0.003 
CRP     
*0 - 10 - - - - 
10 - 49 0.23 (0.08 to 0.39) 0.003 0.23 (0.07 to 0.39) 0.004 
50 - 99 0.41 (0.20 to 0.62) < 0.001 0.41 (0.19 to 0.62) < 0.001 
≥ 100 0.49 (0.28 to 0.70) < 0.001 0.49 (0.27 to 0.71) < 0.001 
Albumin     
< 25 0.62 (0.18 to 1.07) 0.006 0.62 (0.16 to 1.09) 0.009 
25-35 0.48 (0.31 to 0.65) < 0.001 0.48 (0.30 to 0.66) < 0.001 
*≥ 35 - - - - 
Neutrophil count     
<2  0.15 (-0.26 to 0.56) 0.475 0.15 (-0.25 to 0.55) 0.467 
*2-8 - - - - 
≥ 8 0.06 (-0.08 to 0.20) 0.379 0.06 (-0.08 to 0.21) 0.383 
Haemoglobin     
< 80 -0.01 (-0.34 to 0.31) 0.935 -0.01 (-0.34 to 0.31) 0.936 
80-110 0.03 (-0.12 to 0.18) 0.663 0.03 (-0.12 to 0.19) 0.676 
*≥ 110 - - - - 
Constant -3.43 (-3.69 to -3.16) < 0.001 -3.43 (-3.70 to -3.16) < 0.001 
Supplementary Table 3. Common drug combinations. 
Drug combination n % of study population 
(n = 9,584) 
2 drugs Sulphonylureas + metformin 1,012 10.6 
 Insulin + metformin 743 7.8 
 Metformin + DPP-4 inhibitors 458 4.8 
 Insulin + sulphonylureas 370 3.9 
 Sulphonylureas + DPP-4 inhibitors 351 3.7 
 Insulin + DPP-4 inhibitors 233 2.4 
3 drugs Sulphonylureas + metformin + DPP-4 223 2.3 
 Sulphonylureas + insulin + metformin 201 2.1 
 
 
 
